RxDoctor Payments Data

Vytautas Pukis, MD

Internal Medicine · Huntsville, ALNPI 1225270440

Payments from drug & device makers

$16,217in general payments, 2019–2025

Across 1,116 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$984
  • Lilly USA, LLC$787
  • Antares Pharma, Inc.$753
  • plus $9K from 53 others

What the payments were for

  • Food & beverage$16,209100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk201$2,144
AbbVie(2 entities)143$1,768
UCB, Inc.65$1,002
Takeda Pharmaceuticals U.S.A., Inc.54$984
Lilly USA, LLC52$787
Antares Pharma, Inc.50$753
Boehringer Ingelheim39$595
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC45$580
Axsome Therapeutics, Inc.38$563
Pfizer35$537
AstraZeneca35$517
Exact Sciences23$425
Abbott16$401
Tolmar, Inc.21$328
Amgen19$311
GSK15$274
Harmony Biosciences LLC9$235
Supernus Pharmaceuticals, Inc.22$210
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$198
Lundbeck LLC9$192
Biohaven Pharmaceuticals, Inc.9$177
Sanofi-aventis U.S. LLC11$175
Merck10$167
Phathom Pharmaceuticals, Inc.12$161
Kowa Pharmaceuticals America, Inc.10$159
Biohaven Pharmaceutical Holding Company Ltd.7$156
Vanda Pharmaceuticals Inc.11$155
Bayer8$148
Otsuka America Pharmaceutical, Inc.8$142
Astellas Pharma US Inc8$140
Halozyme Inc10$139
Novartis8$138
Idorsia Pharmaceuticals US Inc9$134
Vivus LLC9$129
Johnson & Johnson8$129
Arbor Pharmaceuticals, Inc.8$106
Jazz Pharmaceuticals Inc.5$103
Bausch Health US, LLC6$99
Corium, LLC7$90
Almatica Pharma LLC5$84
Ironwood Pharmaceuticals, Inc6$82
Adlon Therapeutics L.p.6$81
IBSA Pharma Inc.5$79
Xeris Pharmaceuticals, Inc.4$74
Upsher-smith Laboratories LLC3$50
E.r. Squibb & Sons, L.L.C.2$43
Amarin Pharma, Inc.3$42
Assertio Therapeutics, Inc.3$39
Vertex1$30
Melinta Therapeutics, LLC2$28
Ironshore Pharmaceuticals Inc.1$22
Genentech USA, Inc.1$16
Teva Pharmaceuticals USA, Inc.1$15
Tris Pharma Inc1$15
Verity Pharmaceuticals Inc.1$14
Currax Pharmaceuticals LLC1$14
Aytu Biopharma, Inc.1$13
Nalpropion Pharmaceuticals LLC1$13
Eisai Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,217 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$56,429
Medicare patients
135
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$104,273
EliquisApixaban53$49,220
MounjaroTirzepatide44$46,840
TrulicityDulaglutide18$20,936
JardianceEmpagliflozin13$14,241
FarxigaDapagliflozin Propanediol11$12,240
LinzessLinaclotide12$10,976
Tresiba Flextouch U-100Insulin Degludec17$9,501
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,070
MyrbetriqMirabegron13$5,734
Incruse ElliptaUmeclidinium Bromide12$4,105
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen146$3,434
Gabapentin284$2,953
Colchicine25$2,725
Novolog FlexpenInsulin Aspart13$2,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,144$104,273105 claims
Lilly USA, LLCMounjaro, Trulicity$787$67,77662 claims
PfizerEliquis$537$49,22053 claims
Boehringer IngelheimJardiance$595$14,24113 claims
AstraZenecaFarxiga$517$12,24011 claims
GSKTrelegy Ellipta, Incruse Ellipta$274$12,17525 claims
AbbVieLinzess$1,768$10,97612 claims
Astellas Pharma US IncMyrbetriq$140$5,73413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →